TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA.~* All subjects will be required to have been taking a stable dose of methotrexate.~* Active RA at screening defined as greater than or equal to 6 swollen joints.~* The presence of erosive disease~Exclusion Criteria:~* Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed.~* Steroid use greater than 15 mg/day.~* Scheduled for surgery or joint replacement in the hands, wrists or feet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab 180 mg (Type: EXPERIMENTAL): Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
- Denosumab 60 mg (Type: EXPERIMENTAL): Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections on Day 1 and at Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duration of SCI ≥1 year;~* Level of SCI C3-T1, AIS A \& B;~* Age between 18 and 65 years.~Exclusion Criteria:~* Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;~* Known allergies to midodrine hydrochloride;~* PMH of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;~* Hypertension (BP\>140/90 mmHg);~* Untreated thyroid disease;~* Acute illness or infection;~* Current smoker;~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cool Temperature Exposure / No Drug (Type: EXPERIMENTAL): Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
- Cool Temperature Exposure with Drug (Type: EXPERIMENTAL): Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Generally in good health~* Body mass index (BMI) of ≥ 18.0 and ≤ 30.0 kg/m2 at Screening, with minimum weight of 60 kg. (No BMI upper limit for mild AD and amnestic MCI subjects)~* Male subjects and their partners must be willing to comply with the contraceptive requirements of the study. Only female subjects of non-childbearing potential are eligible for participation.~* \[Young subjects\] Male subjects must be aged 18 to 45 years (inclusive) at the time of Screening.~* \[Healthy elder subjects only\] Male and female subjects must be aged 60 to 85 years at the time of screening~* \[Amnestic MCI and Alzheimer's Subjects\] 9. Patients with Alzheimer's disease, with confirmed diagnosis of amnestic mild cognitive impairment, Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).~  1. Either newly diagnosed treatment naïve patients, OR,~ 2. Patients who are currently on standard Alzheimer's Disease treatment may be considered for participation if they are not tolerating treatment and/or they are willing and clinically able to tolerate a discontinuation, 14 days for dose titration + 5x half-lives for washout, or 4 weeks (whichever is longer) prior to randomization. For these patients, the screening window will be allowed for up to 90 days prior to randomization to evaluate discontinuation of symptomatic treatment for Alzheimer's disease.~EXCLUSION CRITERIA:~* Any medical condition that requires chronic medication use.~* History of drug and/or alcohol abuse within 12 months prior to Screening.~* History of having taken another investigational drug within 30 days prior to Admission (Day -1).~* Donation of blood or plasma within 30 days prior to dosing.~* Major surgery within 90 days prior to Admission (Day -1) or anticipated surgery during the study.~* Smokers~* \[Healthy elderly subjects\] Reported changes in cognition and reported history of declines in everyday life in the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- NDX-1017 (Type: EXPERIMENTAL): NDX-1017 will be administered via subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's parent/legal guardian must be willing and able to give written informed consent and the patient must be willing to give written informed assent if applicable~2. Estimated glomerular filtration rate \< 60 mL/min/1.73 m2 body surface area or recipient of a kidney transplant~3. 9-21 years old~4. Able to swallow pills~Exclusion Criteria:~1. Liver failure~2. Malabsorption~3. Current calcium level \>10.5 mg/dL~4. History of hypercalcemia (Ca \>11 mg/dL) during the preceding 6 months~5. Current treatment with an antiepileptic drug or other medications that may affect vitamin D metabolism (e.g., phenobarbital, phenytoin, rifampicin)~6. History of hypervitaminosis D~7. Completion of a course of high dose vitamin D within the preceding 2 months

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- 1000 IU of Vitamin D Daily (Type: ACTIVE_COMPARATOR): Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
- 4000 IU of Vitamin D Daily (Type: EXPERIMENTAL): Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preexisting type 2 diabetes mellitus requiring medical treatment or~* overt diabetes diagnosed prior to 20 weeks of gestation using either Hemoglobin A1c (HBA1C) ≥ 6.5 or fasting glucose ≥126 mg/dl or random blood glucose ≥ 200 mg/dl or two step method ( 50g glucose challenge test (GCT) \>135 mg/dl followed by 100 GCT with at least 2 values above thresholds: Fasting Blood Glucose (FBG) \>90, 1 hr \>180, 2 hr \> 155, 3 hr \> 140 mg/dl).~* Gestational age ≤20 weeks~* Willing to start insulin therapy or to continue insulin treatment during pregnancy~* Singleton or twin pregnancy~Exclusion Criteria:~* Known allergy/prior adverse reaction to NPH/detemir~* Patients \<18y~* Known major fetal anomalies~* Diabetic nephropathy (Creatinine (Cr)≥1.5)~* Diabetic proliferative retinopathy~* Patients with Type 1 diabetes or gestational diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neutral Protamine Hagedorn (NPH) (Type: ACTIVE_COMPARATOR): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
- Detemir (Type: ACTIVE_COMPARATOR): Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients greater than or equal to 18 years old~* Confirmed diagnosis of Cushing's disease or acromegaly~Exclusion Criteria:~* Patients who require surgical intervention~* Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry~* HbA1c \> 10 % at screening~* Known hypersensitivity to somatostatin analogues Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Incretin based therapy (randomized group) (Type: EXPERIMENTAL): Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
- Insulin (randomized group) (Type: EXPERIMENTAL): Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
- Non-Randomized Arm (Type: OTHER): This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~* Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~* Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~* No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Eligibility criteria include, but are not limited to the following:~* Are between the ages of 18 and 80 years.~* Have been diagnosed with rheumatoid arthritis for at least 6 months.~* Have failed treatment (lack of efficacy) with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None
- 7 (Type: PLACEBO_COMPARATOR): None
- 8 (Type: PLACEBO_COMPARATOR): None
- 9 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as assessed by a central reading center~2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye.~3. Willing and able to comply with clinic visits and study-related procedures.~4. Provide signed informed consent.~Key Exclusion Criteria:~1. Evidence of CNV due to any cause other than AMD in either eye~2. Prior IVT anti-VEGF in the study eye~3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients~4. Any history of macular hole of stage 2 and above in the study eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REGN910-3 (3 mg: 2 mg) (Type: EXPERIMENTAL): Participants were administered intravitreal injection of REGN910-3 (3 milligram \[mg\]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
- REGN910-3 (6 mg:2 mg) (Type: EXPERIMENTAL): Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
- Aflibercept (IAI) 2 mg (Type: EXPERIMENTAL): Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supplementation With Cholecalciferol in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 25 (OH) \< 20 ng/ml~* Peritoneal dialysis or hemodialysis \> 3 months~Exclusion Criteria:~* Use of vitamin D or its analogues, corticosteroids and immunosuppressive~* Peritonitis in the previous month at baseline~* Liver, neoplastic, infectious or autoimmune diseases and positive HIV~* Hypercalcemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 100 drops/week for 12 weeks
- Cholecalciferol (Type: ACTIVE_COMPARATOR): Drug: Cholecalciferol - 100,000 IU/week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Applicable disease and eligible for myeloablative SCT~* Patients must have two partially HLA-matched CBUs~* Back-up stem cell source~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched donor able to donate~* Prior allogeneic HSCT~* Other active malignancy~* Active or uncontrolled infection~* Active/symptoms of central nervous system (CNS) disease~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NiCord® (Type: EXPERIMENTAL): NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Azithromycin in the Treatment of Adult Cholera

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 - 60 years~* Gender: Male (To facilitate accurate measurement of stool and urine, and also due to the difficulties in hospitalizing women for longer duration)~* Duration of illness: 24 hours or less~* Written informed consent for participation in the study~* Dehydration status: Signs of severe dehydration as determined by World Health Organization criteria.~* Positive stool dark-field microscopic examination for V. cholerae, and subsequent isolation of V. cholerae O1 or O139 from an admission culture of a stool or rectal swab sample.~Exclusion Criteria:~* History of receiving even one dose of an antimicrobial agent effective in the treatment of cholera, and even a single fose of the drugs under evaluation.~* Concomitant infection requiring antimicrobial therapy other than the study drugs which may interfere with evaluation of either the efficacy or safety of the study drugs.~* A concomitant illness which may confound evaluation of outcome or is a contraindication for use of either of the study drugs (chronic heart, lung, of kidney disease, or instance), or conditions which may confound evaluation of adverse events of the study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the Stayhealthy BC1 Body Comp Analyzer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* boys and girls 10-17 yrs and men and women 18-80 yrs~Exclusion Criteria:~* acute illness~* pregnancy~* pacemaker or defibrillator

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Body composition testing (Type: EXPERIMENTAL): Body composition tested using bioelectrical impedance (BC1) and the DEXA or hydrostatic weighing methods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effective Treatment for Prescription Opioid Abuse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For inclusion in the proposed studies, subjects must be \> 18 years old and in good health. Subjects must meet DSM-IV criteria for opioid dependence and FDA qualification criteria for buprenorphine treatment, including a history of opioid dependence and significant current opioid use (i.e., opioid-positive urines). Subjects must also be seeking or willing to accept opioid detoxification.~Exclusion Criteria:~* Because the primary focus of the proposed research is to develop an efficacious intervention for prescription opioid abuse that employs a buprenorphine taper and subsequent naltrexone maintenance, individuals who require ongoing opioid therapy for pain or other chronic medical conditions will be excluded from participating.~* Individuals with evidence of an active psychiatric disorder that may interfere with consent or participation in the research (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., cardiovascular disease) or who are pregnant or nursing will be excluded from participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1-week buprenorphine taper (Type: EXPERIMENTAL): 1-week buprenorphine taper + behavioral therapy + urine toxicology
- 2-week buprenorphine taper (Type: EXPERIMENTAL): 2-week buprenorphine taper + behavioral therapy + urine toxicology
- 4-week buprenorphine taper (Type: EXPERIMENTAL): 4-week buprenorphine taper + behavioral therapy + urine toxicology

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete